ARS Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SPRY Nasdaq 8731 https://ars-pharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ARS Pharmaceuticals Inc

ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray - May 15th, 2023 6:11 pm
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results - May 15th, 2023 1:00 pm
Why ARS Pharmaceuticals Stock Is Soaring Today - May 12th, 2023 3:51 pm
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis - May 11th, 2023 11:01 pm
ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis - May 9th, 2023 1:10 pm
Companies Like ARS Pharmaceuticals (NASDAQ:SPRY) Are In A Position To Invest In Growth - Apr 21st, 2023 2:05 pm
ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis - Mar 28th, 2023 1:39 pm
ARS Pharmaceuticals Full Year 2022 Earnings: Beats Expectations - Mar 25th, 2023 1:10 pm
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results - Mar 23rd, 2023 8:01 pm
One ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider upped their stake in the previous year - Mar 22nd, 2023 10:19 am
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors - Feb 23rd, 2023 9:01 pm
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis - Feb 22nd, 2023 9:05 pm
ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 - Feb 9th, 2023 11:30 am
Insiders own 34% of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) shares but individual investors control 36% of the company - Feb 9th, 2023 10:43 am
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis - Nov 10th, 2022 1:00 pm